Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.52 |
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.51 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.51 |
| ▸ | MC4R | P32245 | 3/20 | 0.50 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.49 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.48 |
| ▸ | CALCR | P30988 | 1/20 | 0.48 |
| ▸ | MC5R | P33032 | 2/20 | 0.47 |
| ▸ | MC3R | P41968 | 2/20 | 0.47 |
| ▸ | MC1R | Q01726 | 2/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
| ▸ | NPY4R | P50391 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | TFPI | P10646 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10421719 | 0.88 | RAMP3 (0.46) | OPRM1OPRD1NMUR2NMUR1RAMP3 | |
| SCHEMBL7935083 | 0.88 | RAMP3 (0.46) | OPRM1OPRD1NMUR2NMUR1RAMP3 | |
| SCHEMBL30302482 | 0.86 | NMUR2 (0.62) | OPRM1OPRD1NMUR2NMUR1EPHA2 | |
| SCHEMBL5025980 | 0.84 | ACE (0.51) | OPRM1OPRD1 | |
| SCHEMBL5025982 | 0.84 | ACE (0.51) | OPRM1OPRD1 | |
| SCHEMBL29773390 | 0.84 | MC4R (0.53) | OPRM1OPRD1NMUR2NMUR1MC4R | |
| SCHEMBL8780544 | 0.84 | NTSR1 (0.59) | OPRD1NMUR2NMUR1EPHA2RAMP3 | |
| SCHEMBL8780556 | 0.84 | NTSR1 (0.59) | OPRD1NMUR2NMUR1EPHA2RAMP3 | |
| SCHEMBL30832772 | 0.84 | OPRD1 (0.61) | OPRM1OPRD1MC4RMC5RMC3R | |
| SCHEMBL14028489 | 0.84 | ACE (0.55) | OPRM1OPRD1NMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382328-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | JENIUS PHARMA LLC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12454549-B2 | Treatments for diseases and disorders that involve oxidative stress | JENIUS PHARMA, LLC (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4536265-A2 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Jenius Pharma, LLC (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20240132542-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Allegro Pharmaceuticals, LLC | 2024-04-25 | — | — | US | disclosed |
| WO-2023239716-A2 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Allegro Pharmaceuticals, LLC (US) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132542-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | GPX4, GPX1, TXNRD2 | OPRM1 2993/4885OPRD1 2954/4885NMUR2 1853/4885 |
| US-12454549-B2 | Treatments for diseases and disorders that involve oxidative stress | GPX4, GPX1, TXNRD2 | OPRM1 2993/4885OPRD1 2954/4885NMUR2 1853/4885 |
| US-20250382328-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | GPX4, GPX1, TXNRD2 | OPRM1 2993/4885OPRD1 2954/4885NMUR2 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.